| The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis |
44 |
| Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions |
43 |
| Commonalities in epileptogenic processes from different acute brain insults: Do they translate? |
40 |
| Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial |
35 |
| New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives |
34 |
| Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders |
34 |
| Deep brain stimulation for drug-resistant epilepsy |
31 |
| Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients |
29 |
| Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results |
25 |
| Laser ablation for mesial temporal lobe epilepsy: Surgical and cognitive outcomes with and without mesial temporal sclerosis |
24 |
| Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions |
24 |
| Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study |
24 |
| Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force |
21 |
| Machine learning applications in epilepsy |
21 |
| Standards for testing and clinical validation of seizure detection devices |
21 |
| The repertoire of seizure onset patterns in human focal epilepsies: Determinants and prognostic values |
20 |
| Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy |
19 |
| Heart rate variability in epilepsy: A potential biomarker of sudden unexpected death in epilepsy risk |
18 |
| Long-term surveillance of SUDEP in drug-resistant epilepsy patients treated with VNS therapy |
18 |
| Long-term outcomes of status epilepticus: A critical assessment |
18 |
| Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes |
18 |
| Cannabis-based products for pediatric epilepsy: A systematic review |
17 |
| Severe infantile onset developmental and epileptic encephalopathy caused by mutations in autophagy gene WDR45 |
17 |
| The incidence and significance of periictal apnea in epileptic seizures |
17 |
| Seizure-induced microvascular injury is associated withimpaired neurovascular coupling and blood-brain barrierdysfunction |
17 |
| The spectrum of intermediate SCN8A-related epilepsy |
17 |
| Wearable devices for sudden unexpected death in epilepsy prevention |
17 |
| Defining the phenotypic spectrum of SLC6A1 mutations |
17 |
| Laser ablation is effective for temporal lobe epilepsy with and without mesial temporal sclerosis if hippocampal seizure onsets are localized by stereoelectroencephalography |
16 |
| User-based evaluation of applicability and usability of a wearable accelerometer device for detecting bilateral tonic-clonic seizures: A field study |
16 |
| Genetic generalized epilepsies |
16 |
| Diagnostic implications of genetic copy number variation in epilepsy plus |
16 |
| Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial |
15 |
| Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development |
15 |
| Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models |
15 |
| Seizure detection using scalp-EEG |
15 |
| Seizure detection based on heart rate variability using a wearable electrocardiography device |
15 |
| Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study |
15 |
| PCDH19-related epilepsy is associated with a broad neurodevelopmental spectrum |
15 |
| The medical treatment of epilepsy in the elderly: A systematic review and meta-analysis |
14 |
| Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis |
14 |
| Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus |
14 |
| Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression |
14 |
| Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus |
13 |
| Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled ROSE trial |
13 |
| Neuroimaging and connectomics of drug-resistant epilepsy at multiple scales: From focal lesions to macroscale networks |
13 |
| Deep learning applied to whole-brain connectome to determine seizure control after epilepsy surgery |
13 |
| Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission |
13 |
| gamma-Aminobutyric acid receptor alpha 1 subunit loss of function causes genetic generalized epilepsy by impairing inhibitory network neurodevelopment |
13 |
| Referral to evaluation for epilepsy surgery: Reluctance by epileptologists and patients |
13 |
